EN Hikma Putting better health within reach, every day We develop, manufacture and market a broad range of products across the US, the Middle East and North Africa, and Europe. Global business with 31 manufacturing plants and 7 R&D centres Europe We manufacture injectable medicines in Europe, supplying products to the US, the MENA, and Europe. We have high-quality manufacturing plants in Germany, Italy and Portugal. Middle East and North Africa (MENA) The region’s principal player, we create branded generic medicines and are a leading licensing partner. In MENA, we are one of the largest pharmaceutical companies and a ‘partner of choice’. US We are the third largest generic injectable manufacturer and a top ten generic company overall in the US. We have a strong presence in the non-injectables market. Rest of the World We have a small presence beyond our core geographies. Latest news Hikma and Winterlight Labs collaborate to develop biomarkers for Schizophrenia patients in MENA 23 November 2021 Hikma Ventures invests in biotechnology company BioSapien Inc., developer of a patented drug-delivery device intended to reduce the system-wide side effects of chemotherapy treatments 11 November 2021 Hikma continues strong 2021 performance and reiterates full year guidance 4 November 2021 About Worldwide Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

EN Hikma Key financial data $ million 1H21 1H20 Change Constant currency change Revenue 1,216 1,132 7% 7% Core revenue 1,216 1,132 7% 7% Gross profit 616 577 7% 7% Core gross profit 616 577 7% 7% Operating profit 326 297 10% 15% Core operating profit 309 284 9% 15% EBITDA 358 328 9% 14% Core EBITDA 358 328 9% 14% Profit attributable to shareholders 248 212 17% 26% Core profit attributable to shareholders 223 205 9% 18% Basic earnings per share (cents) 107.4 87.6 23% 32% Core basic earnings per share (cents) 96.5 85.3 13% 23% Interim dividend per share (cents) 18.0 16.0 13% - Cash flow from operating activities 224 292 (23)% - Investors Financial information Back to top Useful links About Products Investors News Careers Contact Worldwide Leadership Stay in touch Subscribe to our newsletter Follow us instagram Created with Sketch. © Hikma Pharmaceuticals PLC 2021 Terms of use Cookie policy Disclaimer Privacy policy Community guidelines Our website uses cookies to improve your experience. Some of the cookies we use are essential for parts of our website to operate. By using our website without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.